New Collaboration Formed to Further Develop IBD Drug Ovasave

New Collaboration Formed to Further Develop IBD Drug Ovasave
French biotechnology company TxCell SA, which specializes in the development of T-cell immunotherapy for severe chronic inflammatory and autoimmune diseases, recently published updates on the company’s efforts to develop its lead therapeutic candidate Ovasave® for the treatment of inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis. The company’s collaboration, option, development and licensing agreement with Ferring International Center

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *